Do not administer to young foals less than 4 months of age.
Do not administer in case of known hypersensitivity to the active ingredient or to any other milbemycins and to any other ingredients of the veterinary medicinal product.
EQUEST Oral Gel has been formulated specifically for use in horses only. Dogs or cats may be adversely affected by the concentration of moxidectin in this product if they are allowed to ingest spilled gel or have access to used syringes. Neurological signs (such as ataxia, muscle tremor and convulsions) and digestive clinical signs (such as hypersalivation) were recorded.
Do not use the same syringe to treat more than one animal unless horses are running together or in direct contact with each other on the same premises.
Ataxia, depression, abdominal pain, muscle tremor, flaccid lower lip and swelling of the muzzle could be observed on very rare (less than 1 animal in 10,000 animals treated, including isolated reports) occasions. These adverse effects are usually transient and disappear spontaneously in most cases.
Withdrawal period
Meat and offal: 32 days.
Operator warnings
Do not smoke, drink or eat while handling the product.
The use of protective gloves is recommended.
Wash hands or any exposed area after use.
Avoid direct contact with skin and eyes.
In the event of eye contact, flush the eye with copious amounts of clean water and seek medical advice.
Other precautions regarding impact on the environment
Moxidectin fulfils the criteria for a (very) persistent, bioaccumulative and toxic (PBT) substance; therefore, exposure of the environment to moxidectin must be limited to the extent possible. Treatments should be administered only when necessary and should be based on faecal egg counts or evaluation of the risk of infestation at the animal and/or herd level. In order to reduce the emission of moxidectin to surface water and based on the excretion profile of moxidectin when administered as the oral formulation to horses, treated animals should not have access to watercourses during the first week after treatment.
Like other macrocyclic lactones, moxidectin has the potential to adversely affect non-target organisms:
•Faeces containing moxidectin excreted onto pasture by treated animals may temporarily reduce the abundance of dung feeding organisms. Following treatment of horses with the product, levels of moxidectin that are potentially toxic to dung beetles and flies may be excreted over a period of more than 1 week and may decrease dung fauna abundance.
•Moxidectin is inherently toxic to aquatic organisms including fish. The product should be used only according to the label instructions.